[1] 中华医学会感染病学分会, 中华医学会微生物学与免疫学分会.中国耐碳青霉烯类革兰阴性杆菌感染诊疗及防控指南(2023版)[J].中华传染病杂志, 2023, 41(12):705-740.
[2] 王杉, 陈佰义.创伤后多重耐药菌皮肤软组织感染的诊疗进展[J].中华创伤杂志, 2024, 40(5):478-484.
[3] LI J, WANG H, ZHANG L, et al. Eravacycline for the treatment of carbapenem-resistant enterobacterales and acinetobacter baumannii infections: a systematic review and meta-analysis[J]. J Antimicrob Chemother, 2024, 79(8):198.
[4] ZHANEL G G, CHEUNG D, ADAM H, et al. Review of eravacycline, a novel fluorocycline antibacterial agent[J]. Drugs, 2016, 76(5): 567-588.
[5] HOBBS A L V, GELFAND M S, CLEVELAND K O, et al. A retrospective, multicentre evaluation of eravacycline utilisation in community and academic hospitals[J]. J Glob Antimicrob Resist, 2022, 29: 430-433.
[6] 方凯, 魏常娟.依拉环素治疗RICU老年重症肺炎合并CRAB感染五例[J/OL].中华重症医学电子杂志, 2025:1-8. http://icu.cma-cmcc.com.cn/CN/10.3877/cma.j.issn.2096-1537.2025.05.27-0010.
[7] 俞画秀, 黄民, 邱凯锋. 依拉环素超说明书用药循证评价[J].中国处方药, 2026, 24(2): 16-21. |
